Trehalose alleviates nephropathy in focal segmental glomerulosclerosis via the upregulation of the WT-1/EZH2 pathway
Our findings suggest that trehalose could be a promising therapeutic agent for FSGS, nevertheless, more studies are necessary to confirm our findings and evaluate trehalose efficacy in clinical settings.
Authors
- Fahad Zadjali (ORCID: https://orcid.org/0000-0001-5891-4700)
- Amira Alkharusi (ORCID: https://orcid.org/0000-0002-6671-4431)
- Mohamed S. Al Riyami (ORCID: https://orcid.org/0000-0003-3698-5609)
- Maha Al‐Asmakh (ORCID: https://orcid.org/0000-0001-7855-4001)
- Shadia Al Sinawi
- Amal Kassab
- Zaina Alharthi
- Faisal Al Ismaili
- Suaad Al-Badi
- Razan Al Zadjali
- Sulaiman Al-Hashmi
- Ali Al Lawati
- Sara Al Mashrafi
- Razan Al Breiki
- Miytha Al Marbuii
Institutions
- Oman Medical College (OM)
- University of Nizwa (OM)
- Royal Hospital (OM)
- Sultan Qaboos University Hospital (OM)
- Sultan Qaboos University (OM)
- McGill University (CA)
- Qatar University (QA)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-11-06
- DOI
- https://doi.org/10.3389/fphar.2025.1706617
- Citations
- 1
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 1.43
Funders
- Qatar University
- Sultan Qaboos University